Dimethyltrienolone

Description:

Dimethyltrienolone is a potent oral steroid derived from nandrolone. It is a close cousin of methyltrienolone, differing only by an additional 7-alpha methyl group. This is a modification that only appears a couple of times in commercial steroid medicine, but when it does it seems to have a powerful effect. Its main function is to reduce binding to serum proteins, increasing the percentage of free (active) steroid in the blood and overall steroid potency. We see this with bolasterone, a powerful dimethylated derivative of testosterone that displays nearly six times greater anabolic potency than methyltestosterone. 7-Methylation also appears on Cheque Drops (mibolerone), a 7,17-dimethylated nandrolone with about 41 times the oral anabolic potency of methyltestosterone. Dimethyltrienolone is in the same class as a dimethylated form of trenbolone. It is an extremely potent oral anabolic and androgenic steroid, perhaps far more than any other agent developed before or after. This agent is not widely used by athletes, however, given that it was never produced commercially.

History:

Dimethyltrienolone was first described in 1967.1 This agent is one of a great many potent anabolic steroids that has been developed but never introduced into a commercial drug market. As such, it is a research compound only, and there is no human data on it to report. There are, of course, a great many compounds that fit this description that are not included in this reference. What makes this particular steroid stand out from the others is its sheer potency. More to the point, dimethyltrienolone is perhaps the most potent anabolic steroid that has ever been developed and assayed for effect. This agent is very similar in structure to Metribolone (methyltrienolonel), which was determined to be not only extremely potent, but also the most hepatotoxic steroid ever developed at the time of its testing. That steroid is certainly an agent of extreme proportions, and dimethyltrienolone is only going to be a more potent (and potentially more toxic) derivative.

When this steroid was assayed for anabolic and androgenic effect back in 1967, the results were indeterminate. They were indeterminate because the values were so high they could not be accurately calculated given the parameters of the study. The study itself was very typical. As would be expected of an oral steroid, methyltestosterone was used as the standard of comparison. The animals (rats) were dosed and later sacrificed. Ventral prostate and seminal vesicles were weighed to measure androgenic effect, and levator ani was used for anabolic potency (the same three values that were the standard of analysis for steroids in the 1960’s and ’70’s). In regards to all three measures, dimethyltrienolone was shown to be more than 100 times stronger in effect than methyltestosterone. The numbers, when reported in percentages, simply read ‘> 10,000’ (greater than 10,000%) on all 3 tests. I was unable to find further oral assays on this steroid, making the exact potency (by these experiments or others) unknown.

How Supplied:

Dimethyltrienolone is not available as a commercial agent.

Structural Characteristics:

Dimethyltrienolone is a modified form of nandrolone. It differs by: 1) the addition of a methyl group at carbon 17alpha to protect the hormone during oral administration, 2) the introduction of double bonds at carbons 9 and 11, which increases its binding affinity and slows its metabolism, and 3) the introduction of a methyl group at carbon 7 (alpha), which inhibits steroid attachment to serum-binding proteins like SHBG (Sex Hormone Binding Globulin) and greatly enhances relative biological activity.

Side Effects (Estrogenic):

Dimethyltrienolone is not aromatized by the body, and is not believed to be measurably estrogenic. It is of note, however, that dimethyltrienolone likely displays significant binding affinity for the progesterone receptor.

The side effects associated with progesterone are similar to those of estrogen, including negative feedback inhibition of testosterone production and enhanced rate of fat storage. Progestins also augment the stimulatory effect of estrogens on mammary tissue growth. There appears to be a strong synergy between these two hormones here, such that gynecomastia might even occur with the help of progestins, without excessive estrogen levels. The use of an anti-estrogen, which inhibits the estrogenic component of this disorder, is often sufficient to mitigate gynecomastia caused by progestational anabolic/androgenic steroids.

Side Effects (Androgenic):

Although classified as an anabolic steroid, androgenic side effects are still likely with this substance. This may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss. Women are also warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. Additionally, the 5-alpha reductase enzyme does not metabolize dimethyltrienolone, so its relative androgenicity is not affected by finasteride or dutasteride.

Side Effects (Hepatotoxicity):

Dimethyltrienolone is a c17-alpha alkylated compound. This alteration protects the drug from deactivation by the liver, allowing a very high percentage of the drug entry into the bloodstream following oral administration. C17alpha alkylated anabolic/androgenic steroids can be hepatotoxic. Prolonged or high exposure may result in liver damage. In rare instances lifethreatening dysfunction may develop. It is advisable to visit a physician periodically during each cycle to monitor liver function and overall health. Intake of c17-alpha alkylated steroids is commonly limited to 6-8 weeks, in an effort to avoid escalating liver strain. Note that dimethyltrienolone is an exceedingly potent oral steroid, with a very high level of resistance to hepatic metabolism. This makes dimethyltrienolone exceedingly liver toxic.

The use of a liver detoxification supplement such as Liver Stabil, Liv-52, or Essentiale Forte is advised while taking any hepatotoxic anabolic/androgenic steroids.

Side Effects (Cardiovascular):

Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis.

The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Although not extensively studied in humans, the high relative potency and non-aromatizable nature of dimethyltrienolone suggests that this agent is extremely prone to negatively altering lipid values and increasing atherogenic risk. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.

To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.

Side Effects (Testosterone Suppression):

All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Without the intervention of testosteronestimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.

The above side effects are not inclusive. For more detailed discussion of potential side effects, see the Steroid Side Effects section of this book. Administration (General):

Prescribing guidelines generally advise that oral steroids can be taken with or without meals. The difference in bioavailability is generally not regarded as substantial. However, a 2016 study on newborn infants did find the absorption of oxandrolone to be significantly improved when dissolved directly in fat (MCT oil).2 If the diet includes considerable fat content, taking this oral steroid with meals might be more advantageous.

Administration (Men):

Dimethyltrienolone was never approved for use in humans. Prescribing guidelines are unavailable. This agent is generally not recommended for physique- or performance-enhancing purposes due to its high level of hepatotoxicity.

Those absolutely insisting on its use need to take its level of liver toxicity very seriously. At the very least, routine blood tests should be conducted to ensure the agent is not imparting damage. Drug duration is also usually very limited, typically to 4 weeks of use or less. relative potency of dimethyltrienolone is extremely high, requiring doses as little as .25 (1/4) milligram per day for a pronounced anabolic effect (.25 to 1mg likely being the chosen range). It needs to be emphasized again that there are many other steroids out there worth using before this one, which are not going to be as dangerous. No compound, no matter how potent, is magic, and dimethyltrienolone is one of those steroids that should probably just be left alone.

Administration (Women):

Dimethyltrienolone was never approved for use in humans. Prescribing guidelines are unavailable. This agent is not recommended for women for physique- or performanceenhancing purposes due to its extremely strong toxicity and tendency to produce virilizing side effects.

Availability:

Dimethyltrienolone is not produced as a prescription drug product. This agent is available on the black market as an underground designer steroid, however.

1 Mathieu J. Proc Intern. Symp. Drug Res. (1967):134. Chem Inst. Can.. Montreal, Canada 1967.

2 Congenit Heart Dis. 2016 Jun 3. Use of Oxandrolone to promote Growth in Neonates following Surgery for Complex Congenital Heart Disease: An Open-Label Pilot Trial. Burch PT, Spigarelli MG et al.